Cleminorexton
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cleminorexton ( ; former developmental code name ORX750) is an orexin OX 2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.
Cleminorexton ( ; former developmental code name ORX750) is an orexin OX 2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1366317571 under CC BY-SA 4.0; modifications have been made.